The scientific documentation supporting the potential clinical and economic benefits of a
growing use of off-patent generic drugs in clinical practice seems to be limited in Italy as yet …

Background: The aim of this study was to investigate the impact of selected legislative
initiatives and their implementation for off-patent medicinal products in Slovakia compared …

Introduction/Objectives: This manuscript aims to provide guidance to policymakers with a
view to fostering a fair, competitive and sustainable market for off-patent biologicals and …

Background The use of generics, equivalent but less expensive drugs, is an important
opportunity to reduce healthcare expenditure. Methods The purpose of this study was to …

Biosimilar medicines have shown similarity with the originator biologic and offer a similar
clinical outcome generally at a lower cost. This paper identifies benefits of off-patent …

Generic medicines are those where patent protection has expired, and which may be
produced by manufacturers other than the innovator company. Use of generic medicines …

Background A competitive market for off-patent biologicals leads to more affordable and
high-quality healthcare. In recent years, Belgium has been characterized by its low use of …

Authorized generics are identical in formulation to brand drugs, manufactured by the brand
company but marketed as a generic. Generics, marketed by generic manufacturers, are …

Generic or non-proprietary drugs play an increasing part in the French pharmaceutical
market. These copies of the original brand name medicines are available once drug patents …

Background and objective: Best-value biological medicines may generate competition in the
off-patent biologicals market, resulting in having more resources available to provide …